During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
|Articles|December 9, 2013
MLN9708 in Relapsed Multiple Myeloma Not Refractory to Bortezomib
Author(s)Shaji K. Kumar, MD
Shaji K. Kumar, MD, discusses the results of a phase II trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib.
Advertisement
Clinical Pearls
Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of a phase II trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib.
- 16% of patients had a pre-specified response (minimum minor response by end of Cycle 2 or partial response by end of Cycle 4)
- 35% of patients had partial response or better under the approach of receiving MLN9708 alone and adding dexamethasone if it did not work well
- The most common side effects in this trial (fatigue, drop in platelet counts, nausea, and diarrhea) were well managed
<<<
Advertisement
Related to this article
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
2
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
3
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
4
FET-PET, Molecular Testing, and Personalized Treatment Push Brain Tumor Care Forward
5